A Real-World Study of Trastuzumab Rezetecan in HER2+ Solid Tumors

Clinical trial NCT07387874 · ACTIVE_NOT_RECRUITING

Trial details

NCT number: NCT07387874
Sponsor: Lixiaoling
Status: ACTIVE_NOT_RECRUITING
Study type: OBSERVATIONAL

Recurrent or Metastatic Solid Tumors

Start date: 2025-07-10
Primary completion: 2027-07-01
Enrollment: 30

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.